Description du projet
Le collyre peut perturber la réaction auto-immune dans les maladies oculaires graves
Les maladies inflammatoires oculaires, appelées également uvéites, sont un groupe hétérogène de maladies inflammatoires d’origine infectieuse et auto-immune pouvant entraîner la cécité. Malgré les progrès accomplis grâce au traitement par stéroïdes pour réduire l’inflammation, il n’existe aucun traitement efficace et l’utilisation de stéroïdes à long terme peut provoquer de graves complications. TRS a mis au point une molécule bio-inspirée brevetée qui perturbe le mécanisme auto-immun provoquant ces maladies. Il possède donc le potentiel de traiter l’évolution de la maladie et pas simplement d’améliorer les symptômes. La technologie sera disponible sous forme de collyre et d’injection pour traiter toutes les parties de l’œil en fonction de la maladie spécifique. Le financement de l’UE soutient la mise en place d’essais cliniques, dont les résultats permettront d’obtenir des financements pour la commercialisation.
Objectif
Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences.
Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness.
Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases.
Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market.
In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineophthalmologyglaucoma
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicineimmunology
- social sciencessociologygovernancetaxation
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
3093765 Zichron Yaakov
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.